Lead Product(s) : Lactic Acid,Glycerine
Therapeutic Area : Undisclosed
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 08, 2010
Lead Product(s) : Lactic Acid,Glycerine
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dermacid Silver,Lactic Acid,Glycerine
Therapeutic Area : Undisclosed
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 19, 2010
Lead Product(s) : Dermacid Silver,Lactic Acid,Glycerine
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE,Dextrans,Glycerine
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : OcuMension Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
OcuMension Acquires Alcon Eye Drops with 16.7% Equity, Strategic Partnership Begins
Details : OcuMension will acquire outright, Tears Natural Forte, Bion Tears, Alcaine, Fluorescite, and Cyclogyl, in the Chinese market and AR-15512, a novel topical drug candidate for dry eye.
Product Name : Tears Naturale Forte
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 08, 2024
Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE,Dextrans,Glycerine
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : OcuMension Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Curcuma Longa,Glycerine,Propolis
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Shilpa Medicare Launches 'Oraal’ for Treatment of Oral Mucositis
Details : ORAAL, an oral spray with a naturally derived formulation, which is indicated for the treatment of oral mucositis. The composition of ORAAL is protected by a granted patent in India until November 2033.
Product Name : Oraal
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 13, 2023
Lead Product(s) : Curcuma Longa,Glycerine,Propolis
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Glycerine,Polyethylene Glycol 400
Therapeutic Area : Ophthalmology
Study Phase : Undisclosed
Sponsor : Andover Research Eye Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of the Tolerability and Efficacy of CWT-f-002 Lubricant Eye Drops
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 21, 2022
Lead Product(s) : Glycerine,Polyethylene Glycol 400
Therapeutic Area : Ophthalmology
Highest Development Status : Undisclosed
Sponsor : Andover Research Eye Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Glycerine,Inapplicable
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase I
Sponsor : Dalhousie University
Deal Size : Inapplicable
Deal Type : Inapplicable
The Effects of Glycerol as an Optical Clearing Agent for Visualization of the Middle Ear
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 11, 2022
Lead Product(s) : Glycerine,Inapplicable
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase I
Sponsor : Dalhousie University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Glycerine,Poloxamer,Tyloxapol
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cationorm® Plus (glycerol) is a sterile, preservative-free, artificial tear containing the novel Novasorb® technology. As the only artificial tear that uses positive cationic emulsion to hold hydration in place, it protects, hydrates and lubricates the...
Product Name : Cationorm Plus
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 10, 2022
Lead Product(s) : Glycerine,Poloxamer,Tyloxapol
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Urea,Glycerine
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : University of Sheffield
Deal Size : Inapplicable
Deal Type : Inapplicable
A NOVel Moisturiser for Atopic Dermatitis: Effect on the Skin Barrier
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 03, 2019
Lead Product(s) : Urea,Glycerine
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : University of Sheffield
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Glycerine,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Sponsor : McMaster Surgical Associates | Hamilton Health Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 03, 2014
Lead Product(s) : Glycerine,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Sponsor : McMaster Surgical Associates | Hamilton Health Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Carboxymethyl Cellulose,Glycerine,Sodium Hyaluronate
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 21, 2014
Lead Product(s) : Carboxymethyl Cellulose,Glycerine,Sodium Hyaluronate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
